INTRODUCTION {#S3}
============

Obesity and its related metabolic disorders are increasing at a rate that is considered of epidemic proportions in Western and developing countries. The increasing prevalence of obesity is likely due to a combination of genetic predisposition as well as evolutionary, social, and environmental factors ([@R15]; [@R45]; [@R53]). Data gleaned over the last few years have uncovered the interaction between peripheral signals and brain targets provided by different neuropeptides and neurotransmitters ([@R25]; [@R30]; [@R63]). However, despite initial hope, this knowledge failed to provide a much-needed antiobesity drug ([@R12]; [@R11]; [@R31]). It is generally recognized that to progress in this area it is crucial to discover the basic molecular mechanisms regulating energy homeostasis. Taking into account that almost all signaling proteins used by cells to communicate with its environment are assembled in the endoplasmic reticulum (ER) ([@R50]; [@R47]; [@R15]; [@R13]), studies addressing the molecular mechanisms involved in ER stress functions have started to reveal the molecular mechanisms involved in complex diseases.

The ER is a sophisticated luminal network in which protein synthesis, maturation, folding, and transport take place ([@R50]; [@R32]; [@R47]; [@R15]; [@R13]). The term ER stress refers to the alterations of the protein-folding functionality of the ER, which activates a complex signaling network termed the unfolded protein response (UPR), leading to coordinated transcriptional events promoting attenuation of protein synthesis, upregulation of ER-folding machinery (a type of proteins called chaperones), and degradation of irreversibly misfolded proteins ([@R50]; [@R32]; [@R47]; [@R33]; [@R13]). Previous studies have demonstrated that ER stress and activation of UPR pathways play a major role promoting obesity-induced insulin resistance in peripheral tissues. For example, inflammation, free lipid accumulation, and hyperglycemia in pancreatic β cells and liver elicit activation of the UPR, leading to decreased insulin expression and inhibition of insulin signaling ([@R40], [@R41]; [@R26]; [@R24]; [@R13]). Current evidence also indicates that obesity and overnutrition-induced inflammation causes ER stress in the hypothalamus, inducing insulin and leptin resistance and, ultimately, weight gain ([@R64]; [@R20]; [@R42]; [@R61]; [@R48]; [@R49]). Notably, these studies also demonstrate that pharmacological interventions that improve protein folding (i.e., chemical chaperones) recover leptin and insulin signaling, normalizing body weight ([@R64]; [@R20]; [@R42]; [@R61]; [@R49]).

A current idea gaining credibility is that adipose stores in some obese individuals become saturated and lipotoxic fat metabolites spill over into tissues not suited for lipid storage ([@R58]; [@R34]). Thus, accumulation of reactive lipid species, such as diacylglycerol, free fatty acids, free cholesterol, and ceramides, is a pathogenic mechanism of insulin resistance, type 2 diabetes, and liver and cardiovascular disease. In peripheral tissues, such as β cells, skeletal muscle, liver, and heart, this process, known as lipotoxicity, occurs through inflammation and ER stress ([@R56]; [@R57]; [@R55]). However, despite this evidence, whether (1) lipotoxocity may happen in the hypothalamus and, more specifically, whether (2) ceramide-induced lipotoxicity may induce hypothalamic ER stress or (3) this mechanism is of relevance for obesity is currently unknown. Therefore, the aims of this study were first to determine whether central ceramides elicit ER stress in the hypothalamus, and second to investigate whether that action accounts for the changes in energy balance associated with obesity.

RESULTS {#S4}
=======

Central Ceramide Treatment Induced Hypothalamic ER Stress and Body Weight Gain through Sympathetic Inhibition of BAT {#S5}
--------------------------------------------------------------------------------------------------------------------

Central treatment of C6 ceramide, a cell-penetrating ceramide that is partially converted to long-chain ceramides inside the cell ([@R39]; [@R14]; [@R46]), increased the concentration of C16 ceramide in the mediobasal hypothalamus (MBH), confirming the efficiency of the treatment ([Figure 1A](#F1){ref-type="fig"}). This effect was associated with increased ER stress, as demonstrated by the increased protein concentration of the UPR, such as GRP78/BiP (glucose-regulated protein 78 kDa/binding immunoglobulin protein), pIRE1 (phosphorylated inositol requiring enzyme 1), pPERK (phosphorylated PKR-like ER kinase), peIF2α (phosphorylated eukaryotic initiation factor 2α), ATF6α (activating transcription factor 6 alpha), and CHOP (C/EBP homologous protein) ([@R50]; [@R32]; [@R47]; [@R33]; [@R13]) in the MBH ([Figure 1B](#F1){ref-type="fig"}). Of note, central administration of ceramide induced a marked feeding-independent weight gain ([Figure 1C](#F1){ref-type="fig"}), which was associated with decreased mRNA levels of thermogenic markers in BAT, such as uncoupling proteins 1 and 3 (UCP1 and UCP3), peroxisome-proliferator-activated receptor-gamma coactivator 1 alpha (PGC1α, but not PGC1β), and fatty acid-binding protein 3 (FABP3) ([Figure 1D](#F1){ref-type="fig"}). This was confirmed at the protein level as indicated by the reduced UCP1 protein concentration in BAT ([Figure 1E](#F1){ref-type="fig"}). In keeping with the decreased expression of thermogenic markers, central ceramide-treated rats displayed lower body temperature ([Figure 1F](#F1){ref-type="fig"}). Moreover, central administration of ceramide reduced BAT sympathetic nerve traffic recorded directly by microneurography ([Figures 1G--1H](#F1){ref-type="fig"}).

GRP78 in the Ventromedial Nucleus of the Hypothalamus Reversed the Central Ceramide Effect on Body Weight and BAT Thermogenesis {#S6}
-------------------------------------------------------------------------------------------------------------------------------

To assess the role of ER stress on ceramide-induced actions on energy balance, we targeted GRP78, an ER chaperone that facilitates the proper protein folding acting upstream of the UPR ([@R50]; [@R32]; [@R47]; [@R33]; [@R13]; [@R9]). Thus, an adenovirus encoding GRP78 wild-type (GRP78 WT) together with GFP or control adenovirus expressing GFP alone was injected first into the ventromedial nucleus of the hypothalamus (VMH), a key site modulating BAT ([@R28]; [@R34], [@R36]; [@R59]; [@R2]). Infection efficiency in the VMH was assessed by expression of GFP ([Figure 2A](#F2){ref-type="fig"}) and an increased concentration of GRP78 in the VMH ([Figure 2B](#F2){ref-type="fig"}). The specificity of the VMH dissections was 92.08% (p \< 0.001) when using pro-opiomelanocortin (POMC) as a marker of "contamination" from the neighboring arcuate nucleus of the hypothalamus (ARC). GRP78 adenovirus elicited a marked decrease in four out the five proteins of the UPR tested in the VMH ([Figure 2B](#F2){ref-type="fig"}), without changes in ceramide levels ([Figure 2C](#F2){ref-type="fig"}), indicating that GRP78 was acting downstream of ceramides. Of note, central ceramide treatment increased the expression of inflammatory markers in the hypothalamus such as interleukin 6 (IL6, but not IL1β), phospho-IKKα/β (pIKKα/β), and tumor necrosis factor alpha (TNFα), which is indicative of lipotoxicity ([Figure S1A](#SD1){ref-type="supplementary-material"}). Remarkably, these effects of ceramide were not affected by GRP78 adenovirus ([Figure S1A](#SD1){ref-type="supplementary-material"}), confirming previous evidence that inflammation is upstream to ER stress in the hypothalamus ([@R64]). Moreover, we found that administration of GRP78 adenovirus into the VMH reversed ceramide-induced weight gain without any change in food intake ([Figure 2D](#F2){ref-type="fig"}). GRP78 WT adenovirus did not affect body weight or feeding in vehicle-treated rats ([Figures S1B and S1C](#SD1){ref-type="supplementary-material"}). Central ceramide promoted an increase in the weight of gonadal and inguinal white adipose tissue pads (gWAT and iWAT, respectively), an effect that was reversed by GRP78 adenovirus into the VMH ([Figure 2E](#F2){ref-type="fig"}). In association with the increased adiposity, ceramide-treated rats showed a tendency for higher circulating leptin and triacylglyceride (TAG) levels that was partially reversed by GRP78 WT adenovirus ([Table S1](#SD1){ref-type="supplementary-material"}). The central ceramide-mediated decrease in UCP1 protein levels in the BAT ([Figure 2F](#F2){ref-type="fig"}), BAT temperature ([Figure 2G](#F2){ref-type="fig"}), and body temperature ([Figure 2H](#F2){ref-type="fig"}) were also blunted by administration of GRP78 adenovirus in the VMH. Overall, these changes indicated that the central ceramide-induced ER stress effectively modulated BAT thermogenesis.

Next, GRP78 WT adenoviruses were injected within the ARC ([Figure S1D](#SD1){ref-type="supplementary-material"}), where they promoted an increase of the concentration of GRP78, which was concomitant to decreased levels of ER stress markers ([Figure S1E](#SD1){ref-type="supplementary-material"}). The specificity of the ARC dissections was 83.48% (p \< 0.001), when using steroidogenic factor-1 (SF1) as a marker of contamination from the adjacent VMH. When given into the ARC, GRP78 WT adenovirus did not affect body weight ([Figure S1F](#SD1){ref-type="supplementary-material"}), feeding ([Figure S1G](#SD1){ref-type="supplementary-material"}), or BAT UCP1 protein content ([Figure S1H](#SD1){ref-type="supplementary-material"}).

GRP78 in the VMH Reversed the Central Ceramide Effect on Insulin Resistance {#S7}
---------------------------------------------------------------------------

Given the effects of central ceramide administration on body weight and BAT thermogenesis, we next evaluated its impact on glucose homeostasis and insulin action. Our data showed that central ceramide did not impact glucose tolerance ([Figure 3A](#F3){ref-type="fig"}) but impaired insulin sensitivity, which was reversed by GRP78 adenovirus in the VMH ([Figures 3B and 3C](#F3){ref-type="fig"}).

Inactivation of GRP78 in the VMH Induced ER Stress and Weight Gain and Decreased UCP1 in BAT {#S8}
--------------------------------------------------------------------------------------------

Having shown that GRP78 overexpression in the VMH inhibited central ceramide's anabolic actions, we next investigated whether GRP78 inactivation in the same hypothalamic nucleus would have the opposite effect on body weight and BAT markers. For this, we treated rats with an adenovirus harboring a dominant-negative isoform of GRP78 (GRP78 DN) ([@R52]) in the VMH or the ARC. Infection efficiency was assessed by expression of GFP (similarly to [Figures 2A](#F2){ref-type="fig"} and [S1D](#SD1){ref-type="supplementary-material"} for GRP78 WT) and increased concentration of GRP78 in the VMH or ARC, since GRP78 DN isoform was most likely recognized by GRP78 antibody ([Figures 4A](#F4){ref-type="fig"} and [S2A](#SD1){ref-type="supplementary-material"}). Our data demonstrated that stereotaxic delivery of GRP78 DN induced a significant UPR activation in the VMH ([Figure 4A](#F4){ref-type="fig"}), which accounts for increased ER stress, feeding-independent weight gain ([Figures 4B and 4C](#F4){ref-type="fig"}), and decreased UCP1 concentration in BAT ([Figure 4D](#F4){ref-type="fig"}). On the other hand, despite ER stress induction in the ARC ([Figure S2A](#SD1){ref-type="supplementary-material"}), GRP78 DN adenovirus did not impact body weight ([Figure S2B](#SD1){ref-type="supplementary-material"}), food intake ([Figure S2C](#SD1){ref-type="supplementary-material"}), or UCP1 protein levels in BAT ([Figure S2D](#SD1){ref-type="supplementary-material"}).

GRP78 in the VMH Reversed Ceramide-Induced ER Stress in Obese Zucker Rats {#S9}
-------------------------------------------------------------------------

To elucidate the contribution of ceramide-induced ER stress in the context of obesity, we used obese Zucker rats (OZR). Our data showed increased concentration of ceramide C16 and C18 in the MBH of OZR when compared to lean Zucker rats (LZR) ([Figure 5A](#F5){ref-type="fig"}). In addition, UPR response was increased in the VMH of OZR ([Figure 5B](#F5){ref-type="fig"}), indicating ER stress. Next, we evaluated the effect of GRP78 overexpression in the VMH of LZR and OZR. Our results indicate that stereotaxic injection of GRP78 WT adenovirus into the VMH induced feeding-independent weight loss in OZR, but not in LZR ([Figures 5C and 5D](#F5){ref-type="fig"}), and ameliorated hypothalamic ER stress ([Figure 5E](#F5){ref-type="fig"}) without changes in hypothalamic ceramide levels ([Figures 5F and 5G](#F5){ref-type="fig"}).

GRP78 in the VMH Increased BAT Thermogenesis and Improved the Metabolic Profile of Obese Zucker Rats {#S10}
----------------------------------------------------------------------------------------------------

Next, we investigated the effect of GRP78 WT adenovirus on thermogenesis. Our data showed that reversion of hypothalamic ER stress with GRP78 WT induced a marked increase in UCP1 protein levels in BAT ([Figure 6A](#F6){ref-type="fig"}), as well as increased BAT ([Figure 6C](#F6){ref-type="fig"}) and core temperature ([Figure 6E](#F6){ref-type="fig"}) in OZR, indicating increased thermogenesis. These effects were associated with an improvement in the metabolic phenotype of OZR, as demonstrated by decreased hepatic steatosis ([Figure 6G](#F6){ref-type="fig"}) associated with reduced levels of acetyl-coenzyme A carboxylase alpha (ACCα; data not shown) and iWAT weight ([Figure 6I](#F6){ref-type="fig"}) and reduced circulating cholesterol and TAG levels ([Table S2](#SD1){ref-type="supplementary-material"}). Of note, no changes were detected in LZR rats treated with the GRP78 WT adenovirus ([Figures 6A, 6B, 6D, 6F, and 6H](#F6){ref-type="fig"}).

GRP78 in the VMH Improves Leptin Signaling and Insulin Resistance in Obese Zucker Rats {#S11}
--------------------------------------------------------------------------------------

Administration of GRP78 WT adenovirus into the VMH did not affect the protein levels of pSTAT3 (phosphorylated signal transducer and activator of transcription 3), pPI3K (phosphorylated phosphatidylinositide 3-kinase), phosphorylated AKT (pAKT), and SOCS3 (suppressor of cytokine signaling 3) in the VMH of LZR rats ([Figure 7A](#F7){ref-type="fig"}). GRP78 WT adenoviruses induced significantly the concentration of pSTAT3, pPI3K, and pAKT in the VMH of OZR, whereas SOCS3 levels were reduced ([Figure 7B](#F7){ref-type="fig"}).

Administration of GRP78 WT adenovirus into the VMH did not affect glucose tolerance in either LZR or OZR, although they reduced insulin circulating levels as early as 30 min after glucose administration in OZR ([Figures 7C and 7D](#F7){ref-type="fig"}). On the other hand, GRP78 WT adenoviruses tended to increase insulin sensitivity in LZR ([Figure 7E](#F7){ref-type="fig"}). Notably, this effect was more pronounced in OZR, where a significant improvement in insulin resistance was found ([Figure 7F](#F7){ref-type="fig"}). In keeping with these data, GRP78 WT adenovirus increased the levels of pAKT in the muscle ([Figure 7H](#F7){ref-type="fig"}) and the levels of pPI3K and pAKT in the liver ([Figure 7J](#F7){ref-type="fig"}) of OZR. No significant changes were observed in LZR ([Figures 7G and 7I](#F7){ref-type="fig"}). Overall, this evidence demonstrates that GRP78 WT into the VMH treatment improves insulin sensitivity in OZR.

DISCUSSION {#S12}
==========

This study identifies a physiological link among ceramides, hypothalamic ER stress, and the modulation of energy balance. Specifically, we show that ceramide-induced hypothalamic lipotoxicity and ER stress elicits decreased sympathetic tone to BAT, which leads to decreased thermogenesis and feeding-independent weight gain. In addition, we show that genetic modulation of the ceramide-induced ER stress pathway in a specific hypothalamic nucleus, the VMH, modulates energy balance by influencing BAT thermogenesis in a sympathetic nervous system (SNS)-mediated manner and insulin sensitivity, as well as by promoting an overall improvement of the metabolic phenotype of leptin and insulin resistant obese Zucker rats.

Ceramides comprise a family of simple sphingolipids generated from fatty acid and sphingosine ([@R3]; [@R8]). Although ceramides are present at low levels within biological membranes, they make important contributions to cell membrane structure. In addition, ceramides exert diverse regulatory effects on cell-signaling pathways that mediate growth, proliferation, motility, adhesion, differentiation, senescence, and apoptosis ([@R18]; [@R16]; [@R10]). Increased ceramide production can lead to ER stress, a mechanism underlying insulin resistance and liver diseases ([@R23]; [@R18]; [@R3]; [@R8]). In keeping with this, systemic pharmacological inhibition or global genetic ablation of de novo synthesis of ceramides improves insulin sensitivity and glucose homeostasis ([@R54]; [@R62]) and protects against glucocorticoid-, saturated fat-, and obesity-induced insulin resistance ([@R19]). Current evidence indicates that brain ceramide levels are increased during high-fat diet-induced obesity ([@R4]) and in streptozotocin-induced diabetic rats ([@R6]). Also, hypothalamic ceramide levels regulated by carnitine palmitoyltransferase 1c (CPT1c, a specific isoform located in the ER), mediate the orexigenic effect of ghrelin ([@R46]). Finally, current evidence has related hippocampal ceramides with impaired energy balance and weight gain ([@R44]). However, despite of this evidence, no data have linked hypothalamic ceramide-induced lipotoxicity with ER stress and energy homeostasis. Therefore, we hypothesized that positive energy balance in obesity might be mediated by specific alterations in hypothalamic ceramide levels and ER stress.

Our data demonstrate that central administration of C6 ceramide (which acts as a long-chain ceramide precursor) increases the C16 ceramide concentration in the ventromedial hypothalamus. Of note, this effect was associated with feeding-independent weight gain, hypothalamic inflammation (leading to lipotoxicity), and increased concentration of UPR proteins (a functional indicator of elevated ER stress), alongside with a decrease in SNS firing and thermogenic capacity of BAT. To determine the physiological relevance of these observations, we investigated whether selective modulation of hypothalamic UPR (and then ER stress) was sufficient to overrule central ceramide's effects in vivo. For this purpose, we focused on the chaperone GRP78 (also called BiP). GRP78 is the most abundant ER-resident chaperone that can prevent accumulation of unfolded/misfolded proteins within the ER ([@R50]; [@R32]; [@R47]; [@R33]; [@R13]; [@R9]). Our data showed that chronic intracerebroventricular (ICV) ceramide administration increased GRP78 protein concentration in the MBH, as and adaptive response to ameliorate ER stress. To test this possibility, we treated rats with adenoviral particles overexpressing GRP78 specifically within the VMH, which is known to control BAT thermogenesis through the SNS ([@R5]; [@R28]; [@R35], [@R36]; [@R59]; [@R2]). We show that GRP78 overexpression in the VMH reduces ER stress and reverses the anabolic effects of central ceramide administration by promoting weight loss (independently of food intake), increasing UCP1 protein content in BAT, and thermogenesis. Conversely, inactivation of GRP78 (by adenoviral-driven expression of DN isoforms) within the VMH promotes ER stress and increases body weight in a feeding-independent manner, in association with decreased UCP1 expression in BAT. Remarkably, no effect on body weight or BAT thermogenesis was detected when GRP78 was targeted (by using either WT or DN adenoviruses) in the neighboring ARC, which has been primarily involved in the regulation of feeding, rather than energy expenditure ([@R63]; [@R60]; [@R29]). Overall, these data suggest that ceramides and GRP78 regulate energy balance in anatomical-specific pattern. In keeping with this concept, ceramide-induced insulin resistance is also improved when GRP78 was overexpressed within the VMH that is also recognized as key site modulating glucose homeostasis ([@R37], [@R38]). Although, classically, the VMH is considered to be a regulator of feeding control ("the satiety center"), our data reinforce recent proofs revealing a more complex physiological role. These data support the idea that the VMH is a fundamental brain area in the regulation of thermogenesis and energy balance, integrating peripheral signaling (i.e., thyroid hormones, bone morphogenetic protein 8b, estradiol, and glucagon like peptide-1) and metabolite sensing (i.e., fatty acids and ceramides) with cellular energy sensors (i.e., AMP-activated protein kinase) ([@R37], [@R38]; [@R27], [@R28]; [@R59]; [@R36]; [@R2]) and now with cellular machinery, namely ER stress and UPR.

A typical problem associated with malfunction of the central mechanism governing energy balance is the development of resistance to peripheral signals, such as insulin and leptin ([@R7]; [@R21]). Current evidence has demonstrated that one of the pathological mechanisms of leptin resistance is hypothalamic ER stress ([@R64]; [@R20]; [@R42]; [@R61]; [@R48]; [@R49]). Remarkably, these studies demonstrate that pharmacological interventions that improve protein folding (i.e., chemical chaperones) recover leptin and insulin signaling, normalizing body weight ([@R64]; [@R20]; [@R42]; [@R61]; [@R49]). Nevertheless, most of the current evidence has been related to the ARC (i.e., melanocortin neurons) and feeding. Here, we focused on the pathophysiological relevance of ER stress in the VMH using a well-established model of leptin resistance, the OZR, which presents a defective leptin receptor signaling ([@R43]). We observed increased hypothalamic ceramide levels in Zucker rats, associated with increased UPR and ER stress in the VMH. Next, we stereotaxically treated OZR with an adenovirus harboring GRP78 into the VMH. That paradigm recapitulated the previous data, with GRP78 promoting an amelioration of the hypothalamic ER stress associated with marked negative energy balance in OZR, leading to increased BAT thermogenesis, and improved metabolic profile as indicated by the weight loss and the increased leptin signaling and insulin sensitivity, as well as reduced liver steatosis and circulating lipid levels. Notably, these effects were totally independent of feeding behavior, as food intake remained unchanged after the adenoviral treatment. Overall, these data indicate that modulation of ER stress in the VMH ameliorates obesity in an extreme model of leptin resistance, which is a condition in human obesity ([@R7]; [@R21]).

Conventionally, the toxic effects of the accumulation of lipids, such as ceramides, have been located in peripheral tissues, such as pancreatic β cells, and liver, heart, and skeletal muscle, where they have been linked with inflammation and the pathophysiology of insulin resistance, type 2 diabetes, liver disease, atherosclerosis, and cardiovascular disease ([@R56]; [@R57]; [@R55]). Of note, lipotoxicity can also occur in the CNS, as observed in certain neurodegenerative disorders (i.e., polyglutamine diseases, Parkinson's disease, and amyotrophic lateral sclerosis) ([@R22]). However, one key question that remained to be addressed relates the status of lipid metabolism and whether accumulation of specific lipid species occurs in the hypothalamus, leading to lipotoxicity, which might have deleterious effects on energy homeostasis. Here, we present evidence demonstrating that ceramides play a key role within the hypothalamus to modulate energy balance through induction of lipotoxicity ER stress and modulation of BAT function. Thus, our data provide an alternative hypothalamic-centered paradigm showing that amelioration of central ER stress leads to a marked improvement in weight gain in a genetic model of obesity. Overall, these data identify a network involving central ceramides, hypothalamic lipotoxicity, ER stress, and VMH-regulated BAT thermogenesis as a pathophysiological mechanism promoting obesity and a promising target for therapeutic intervention.

EXPERIMENTAL PROCEDURES {#S13}
=======================

Animals {#S14}
-------

Male Sprague-Dawley rats (200--250 g; Animalario General University of Santiago de Compostela (USC), Santiago de Compostela, Spain and Charles River Laboratories) and obese Zucker rats (OZR; fa/fa; 300--350 g) and their controls, LZR (fa/−; 250--300 g), both provided by Charles River, were used for the experiments. All animals were housed on a 12 hr light (8:00 to 20:00), 12 hr dark cycle, in a temperature- and humidity-controlled room. The animals were allowed free access to standard laboratory pellets of rat chow and tap water. In all the experimental settings, animals and their food were weighed daily at the beginning of the light phase. The experiments were performed in agreement with the International Law on Animal Experimentation and were approved by the USC Local Ethical Committee, the Xunta de Galicia (Project ID 15010/14/006), and the University of Iowa Institutional Animal Care and Use Committee.

Implantation of Intracerebroventricular Cannulae and Central Treatments {#S15}
-----------------------------------------------------------------------

Chronic ICV cannulae were implanted under ketaminexylazine anesthesia (50 mg/kg, intraperitoneal), as described previously, and correct positioning in the lateral ventricle was confirmed by postmortem histological examination ([@R27], [@R28]; [@R59]; [@R36]). A catheter tube was connected from the brain infusion cannulae to an osmotic minipump flow moderator (model 2001; Alzet). The minipump was inserted in a subcutaneous pocket on the dorsal surface of the animal, created using blunt dissection. The incision was closed with surgical sutures. The rats were then infused with C6 ceramide (N-hexanoyl-D-sphingosine; 1.25 mg/ml dissolved in saline containing one-third DMSO; Sigma-Aldrich) or vehicle (saline containing one-third DMSO; control rats) for 5 days. The selection of these doses was based on previous reports ([@R46]). The animals were caged individually and used for experimentation 5--7 days later. During this postoperative recovery period, the rats became accustomed to the handling procedure under nonstressful conditions.

Stereotaxic Microinjection of Adenoviral Expression Vectors {#S16}
-----------------------------------------------------------

Rats were placed in a stereotaxic frame (David Kopf Instruments) under ketamine-xylazine anesthesia. The VMH and ARC were targeted bilaterally using a 25G needle (Hamilton). The injections were directed to the following stereotaxic coordinates: (1) for the VMH, 2.4/3.2 mm posterior to the bregma (two injections were performed in each VMH), ±0.6 mm lateral to midline and 10.1 mm ventral; and (2) for the ARC, 2.8 posterior to bregma, ±0.3 mm lateral to midline and 10.2 mm ventral, as previously reported ([@R27]; [@R28]; [@R59]; [@R36]; [@R2]). Adenoviral vectors (Viraquest) containing GFP (used as control), GRP78 WT (at 10^12^ particles/ml), GRP78 DN (dominant-negative, at 10^8^ particles/ml) ([@R17]) were delivered at a rate of 200 nl/min for 5 min (1 μl/injection site) as previously reported ([@R27], [@R28]; [@R59]; [@R36]; [@R2]). Animals were treated for 6--9 days.

Glucose and Insulin Tolerance Tests {#S17}
-----------------------------------

Seven days after stereotaxic surgery, blood glucose levels were measured at 0, 15, 30, and 60 min after glucose or insulin administration with an glucometer (Accucheck, Roche) after an intraperitoneal injection of 0.75 U/kg insulin (Actrapid, Novonordisk) for insulin tolerance test (ITT) or 2 mg/g D-glucose (Sigma-Aldrich) administered orally via gavage for glucose tolerance test (GTT) ([@R1]). In this case, the animals were fasted overnight. To assay insulin sensitivity, insulin (100 U/ml; Actrapid, Novonordisk) was injected in the portal vein. Thirty seconds after the insulin injection, the liver was removed, and 90 s later the gastrocnemius muscle was extracted. All samples were immediately homogenized on ice.

Ceramide Quantification {#S18}
-----------------------

Ceramides were extracted and analyzed via an liquid chromatography-electrospray ionization/multistage mass spectrometry system (API 3000 PE Sciex; Spectralab Scientific) in positive ionization as formerly described ([@R46]). Concentrations were measured by multiple reaction monitoring experiments using N-heptadecanoyl-D-erythrosphingosine (C17- ceramide) as an internal standard (50 ng/ml). The method was linear over the range from 2 to 600 ng/ml using as patrons N-palmitoyl-D-erythro-sphingosine (C16 ceramide) and N-stearoyl-D-erythro-sphingosine (C18 ceramide; Avanti Polar Lipids).

Sample Processing and Analytical Methods {#S19}
----------------------------------------

Sample processing, serum analyses, temperature measurements, sympathetic nerve activity (SNA) recording, real-time quantitative PCR, western blotting, and immunohistochemistry were performed as described previously ([@R27], [@R28]; [@R59]; [@R35], [@R36]; [@R51]; [@R2]) (see the [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"} for detailed protocols).

Statistical Analysis {#S20}
--------------------

Data are expressed as mean ± SEM. mRNA, and protein data were expressed in relation (%) to control (vehicle or GFP-treated) rats. SNA was expressed as a percent change from baseline. Statistical significance was determined by t-Student when two groups were compared or ANOVA and post hoc two-tailed Bonferroni test when more than two groups were compared. p \< 0.05 was considered significant.
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======================
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![Effect of Central Administration of Ceramide on Energy Balance\
Ceramide levels in the mediobasal hypothalamus (MBH) (A), representative western blot autoradiographic images (B, left; spliced bands loaded in the same gel) and hypothalamic protein levels of UPR (B, right), body weight change (C, left) and daily food intake (C, right), mRNA expression in the BAT (D), representative western blot autoradiographic images (E, left; spliced bands loaded in the same gel) and protein levels of BAT UCP1 (E, right), rectal temperature (F), BAT sympathetic nervous activity (SNA) tracings (G), and change in BAT SNA of rats centrally treated with vehicle or ceramide 6 (H). Error bars represent SEM; n = 5--7 (SNA recordings) or n = 7--26 animals per experimental group. \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001 versus vehicle, \#p \< 0.05 ceramide 0.2 μg ICV versus ceramide 0.1 μg ICV.](nihms835013f1){#F1}

![Effect of GRP78 Overexpression in the VMH on Central Ceramide Actions and Energy Balance\
(A--C) Representative immunofluorescence (A, left: 4×, scale bar, 300 μm; A, right: 20×, scale bar 100 μm) with anti-GFP showing GFP expression in the VMH, representative western blot autoradiographic images (B, left; spliced bands loaded in the same gel) and hypothalamic protein levels of UPR (B, right; see [Figure S1A](#SD1){ref-type="supplementary-material"} for analysis of inflammatory markers in the hypothalamus), and ceramide levels (C) in the mediobasal hypothalamus of rats treated with GFP or GRP78 WT adenoviruses into the VMH.\
(D--H) Body weight change (D, left) and daily food intake (D, right); weight of iBAT, gWAT, and iWAT pads (E); representative western blot autoradiographic images (F, left; spliced bands loaded in the same gel) and protein levels of BAT UCP1 (F, right); representative infrared thermal images (G, left) and temperature of the BAT area (G, right); and rectal temperature (H) of rats centrally treated with vehicle or ceramide and stereotaxically treated with GFP or GRP78 WT adenoviruses into the VMH. In order to simplify (D)--(H), the vehicle Ad GRP78 WT group has been omitted; in any case, it is important to note that no differences were found in that group when compared to vehicle Ad GFP (see [Figures S1B and S1C](#SD1){ref-type="supplementary-material"}).\
Error bars represent SEM; n = 6 (fat pads and temperature) or 7--47 animals per experimental group. 3V, third ventricle; ME, median eminence. \*p \< 0.05, \*\* p \< 0.01, and \*\*\*p \< 0.001 versus Ad GFP or vehicle Ad GFP; \#p \< 0.05, \#\# p \< 0.01, and \#\#\#p \< 0.001 ceramide Ad GFP versus ceramide Ad GRP78 WT. See [Figures S1D--S1H](#SD1){ref-type="supplementary-material"} for analysis of GRP78 WT adenoviruses in the arcuate nucleus of the hypothalamus.](nihms835013f2){#F2}

![Effect of GRP78 Overexpression in the VMH on Central Ceramide Actions on Glucose Homeostasis and Insulin Sensitivity\
Glucose tolerance test (GTT) (A), insulin tolerance test (ITT) (B), and area under the curve (AUC) (C) from ITT of rats centrally treated with vehicle or ceramide and stereotaxically treated with GFP or GRP78 WT adenoviruses into the VMH. Error bars represent SEM; n = 7--9 animals per experimental group. \*p \< 0.05 versus vehicle Ad GFP; \# p \< 0.05 ceramide Ad GFP versus ceramide Ad GRP78 WT.](nihms835013f3){#F3}

![Effect of GRP78 Inhibition in the VMH on Energy Balance\
Representative western blot autoradiographic images (A, left; spliced bands loaded in the same gel) and hypothalamic protein levels of UPR (A, right), body weight change (B), daily food intake (C), and representative western blot autoradiographic images (D, left; spliced bands loaded in the same gel) and protein levels of BAT UCP1 (D, right) of rats treated with GFP or GRP78 DN adenoviruses into the VMH. Error bars represent SEM; n = 7--9 animals per experimental group. \*p \< 0.05, \*\* p \< 0.01, and \*\*\*p \< 0.001 versus Ad GFP. See [Figure S2](#SD1){ref-type="supplementary-material"} for analysis of GRP78 DN adenoviruses in the arcuate nucleus of the hypothalamus.](nihms835013f4){#F4}

![Effect of GRP78 Overexpression in the VMH of Obese Zucker Rats on Energy Balance\
(A and B) Ceramide levels in the mediobasal hypothalamus (A) and representative western blot autoradiographic images (B, left; spliced bands loaded in the same gel) and hypothalamic protein levels of UPR (B, right) in LZR and OZR.\
(C--G) Body weight change (C and D, left) and daily food intake (C and D, right) from LZR and OZR, respectively; representative western blot autoradiographic images (E, left; spliced bands loaded in the same gel) and VMH protein levels of UPR from OZR (E, right); and ceramide levels in the mediobasal hypothalamus of LZR (F) and OZR (G) stereotaxically treated with GFP or GRP78 WT adenoviruses into the VMH.\
Error bars represent SEM; n = 7--33 animals per experimental group. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 versus LZR or OZR Ad GFP.](nihms835013f5){#F5}

![Effect of GRP78 Overexpression in the VMH of Obese Zucker Rats on BAT Thermogenesis and Liver Steatosis\
Representative western blot autoradiographic images (A, left; spliced bands loaded in the same gel) and protein levels of BAT UCP1 (A, right); representative infrared thermal images (B and C, left) and temperature of the BAT area (B and C, right); rectal temperature (D and E); representative oil red O-stained liver sections (F and G, left; scale bar, 50 μm) and their quantification (F and G, right panel); and weight of iBAT, gWAT, and iWAT pads from LZR (H) and OZR (I) stereotaxically treated with GFP or GRP78 WT adenoviruses into the VMH. Error bars represent SEM; n = 7--9 animals per experimental group. \*p \< 0.05 and \*\*p \< 0.01 versus LZR or OZR Ad GFP; \#\#p \< 0.01 OZR Ad GFP versus OZR Ad GRP78 WT.](nihms835013f6){#F6}

![Effect of GRP78 Overexpression in the VMH of Obese Zucker Rats on Leptin Signaling, Glucose Homeostasis, and Insulin Sensitivity\
Representative western blot autoradiographic images (A and B, left; spliced bands loaded in the same gel) and hypothalamic protein levels of leptin signaling pathway in the VMH (A and B, right) from LZR and OZR; GTT (C and D, left) and serum insulin concentration after 30 min of glucose administration (C and D, right); ITT (E and F, left) and area under the curve (AUC) from ITT (E and F, right); and representative western blot autoradiographic images (G--J, left; spliced bands loaded in the same gel) and protein levels of insulin signaling pathway in skeletal muscle and liver (G--J, right) of LZR and OZR stereotaxically treated with GFP or GRP78 WT adenoviruses into the VMH. Error bars represent SEM; n = 6 (pAKT and pPI3K in LZR) or n = 7--10 animals per experimental group. \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001 versus LZR Ad GFP or OZR Ad GFP.](nihms835013f7){#F7}

###### Highlights

1.  Ceramides induce hypothalamic lipotoxicity and ER stress, leading to weight gain

2.  The chaperone GRP78/BiP in the hypothalamus abolishes ceramide action

3.  Genetic inhibition of hypothalamic GRP78 induces weight gain

4.  Obese Zucker rats show elevated hypothalamic ceramides and ER stress

[^1]: Co-first author
